LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands
LiveWorld (OTC: LVWD) has unveiled its first AI Brand Reputation Index, analyzing how artificial intelligence influences perceptions of 50 leading pharmaceutical brands. The study, released on April 15, 2025, employs LiveWorld's proprietary AI framework to evaluate seven weighted reputation factors across major language models including ChatGPT, Perplexity, and Grok.
The index revealed that established brands like Dupixent and Keytruda maintain strong AI reputations due to clinical effectiveness and healthcare professional trust. Notably, Vertex Pharmaceuticals' Trikafta topped the rankings despite advertising, while newer therapies like Leqvio and Rybrevant struggle with AI visibility. The study also highlighted how safety concerns impact AI-driven reputation for products like Remicade and Xeljanz.
The assessment factors included:
- Efficacy
- Safety
- Healthcare professional trust
- Consumer sentiment
- Digital visibility
- Affordability
- Patient loyalty
LiveWorld (OTC: LVWD) ha presentato il suo primo Indice di Reputazione del Marchio basato sull'Intelligenza Artificiale, analizzando come l'IA influenzi la percezione di 50 dei principali marchi farmaceutici. Lo studio, pubblicato il 15 aprile 2025, utilizza il framework proprietario di LiveWorld per valutare sette fattori di reputazione ponderati attraverso i principali modelli linguistici come ChatGPT, Perplexity e Grok.
L'indice ha mostrato che marchi consolidati come Dupixent e Keytruda mantengono una solida reputazione AI grazie all'efficacia clinica e alla fiducia dei professionisti sanitari. In particolare, Trikafta di Vertex Pharmaceuticals ha raggiunto la vetta della classifica nonostante la pubblicità, mentre terapie più recenti come Leqvio e Rybrevant faticano a emergere nella visibilità AI. Lo studio ha inoltre evidenziato come le preoccupazioni legate alla sicurezza influenzino la reputazione guidata dall'IA per prodotti come Remicade e Xeljanz.
I fattori valutati includevano:
- Efficacia
- Sicurezza
- Fiducia dei professionisti sanitari
- Sentimento dei consumatori
- Visibilità digitale
- Convenienza
- Fedeltà dei pazienti
LiveWorld (OTC: LVWD) ha lanzado su primer Índice de Reputación de Marca basado en Inteligencia Artificial, analizando cómo la IA influye en la percepción de 50 marcas farmacéuticas líderes. El estudio, publicado el 15 de abril de 2025, utiliza el marco propietario de LiveWorld para evaluar siete factores ponderados de reputación a través de los principales modelos de lenguaje como ChatGPT, Perplexity y Grok.
El índice reveló que marcas consolidadas como Dupixent y Keytruda mantienen una fuerte reputación en IA debido a su eficacia clínica y la confianza de los profesionales de la salud. Destaca que Trikafta de Vertex Pharmaceuticals encabezó el ranking a pesar de la publicidad, mientras que terapias más nuevas como Leqvio y Rybrevant tienen dificultades para ganar visibilidad en IA. El estudio también resaltó cómo las preocupaciones de seguridad afectan la reputación impulsada por IA de productos como Remicade y Xeljanz.
Los factores evaluados incluyeron:
- Eficacia
- Seguridad
- Confianza de profesionales de la salud
- Sentimiento del consumidor
- Visibilidad digital
- Asequibilidad
- Lealtad del paciente
LiveWorld (OTC: LVWD)는 인공지능이 50개 주요 제약 브랜드에 대한 인식에 어떻게 영향을 미치는지 분석한 첫 번째 AI 브랜드 평판 지수를 공개했습니다. 2025년 4월 15일 발표된 이 연구는 LiveWorld의 독자적인 AI 프레임워크를 사용하여 ChatGPT, Perplexity, Grok 등 주요 언어 모델을 통해 7가지 가중 평판 요소를 평가했습니다.
지수 결과, Dupixent과 Keytruda 같은 기존 브랜드는 임상 효과와 의료 전문가의 신뢰 덕분에 강한 AI 평판을 유지하고 있습니다. 특히 Vertex Pharmaceuticals의 Trikafta는 광고에도 불구하고 순위 1위를 차지했으며, Leqvio와 Rybrevant 같은 신생 치료제는 AI 가시성에서 어려움을 겪고 있습니다. 또한 연구는 Remicade와 Xeljanz 같은 제품의 안전성 문제들이 AI 기반 평판에 미치는 영향을 강조했습니다.
평가 요소는 다음과 같습니다:
- 효능
- 안전성
- 의료 전문가 신뢰
- 소비자 감정
- 디지털 가시성
- 가격 적정성
- 환자 충성도
LiveWorld (OTC : LVWD) a dévoilé son premier Indice de Réputation de Marque basé sur l'Intelligence Artificielle, analysant comment l'IA influence la perception de 50 grandes marques pharmaceutiques. L'étude, publiée le 15 avril 2025, utilise le cadre propriétaire de LiveWorld pour évaluer sept facteurs de réputation pondérés à travers les principaux modèles linguistiques tels que ChatGPT, Perplexity et Grok.
L'indice a révélé que des marques établies comme Dupixent et Keytruda conservent une forte réputation IA grâce à leur efficacité clinique et à la confiance des professionnels de santé. Notamment, Trikafta de Vertex Pharmaceuticals a dominé le classement malgré la publicité, tandis que des thérapies plus récentes comme Leqvio et Rybrevant peinent à gagner en visibilité IA. L'étude a également souligné comment les préoccupations liées à la sécurité impactent la réputation pilotée par l'IA pour des produits comme Remicade et Xeljanz.
Les facteurs évalués comprenaient :
- Efficacité
- Sécurité
- Confiance des professionnels de santé
- Sentiment des consommateurs
- Visibilité numérique
- Accessibilité financière
- Loyauté des patients
LiveWorld (OTC: LVWD) hat seinen ersten KI-Markenreputationsindex vorgestellt, der untersucht, wie künstliche Intelligenz die Wahrnehmung von 50 führenden Pharma-Marken beeinflusst. Die Studie, veröffentlicht am 15. April 2025, verwendet LiveWorlds eigenes KI-Framework, um sieben gewichtete Reputationsfaktoren über große Sprachmodelle wie ChatGPT, Perplexity und Grok zu bewerten.
Der Index zeigte, dass etablierte Marken wie Dupixent und Keytruda aufgrund klinischer Wirksamkeit und Vertrauen von Gesundheitsfachkräften eine starke KI-Reputation behalten. Bemerkenswert ist, dass Trikafta von Vertex Pharmaceuticals trotz Werbung die Spitze der Rangliste erreichte, während neuere Therapien wie Leqvio und Rybrevant mit der KI-Sichtbarkeit kämpfen. Die Studie hob zudem hervor, wie Sicherheitsbedenken die KI-gesteuerte Reputation von Produkten wie Remicade und Xeljanz beeinflussen.
Bewertete Faktoren waren:
- Wirksamkeit
- Sicherheit
- Vertrauen von Gesundheitsfachkräften
- Verbraucherstimmung
- Digitale Sichtbarkeit
- Bezahlbarkeit
- Patiententreue
- First comprehensive AI Brand Reputation Index for pharmaceutical industry
- Proprietary evaluation framework across major AI language models
- Potential revenue stream from customized brand reputation reports
- to analysis of only 50 pharmaceutical brands
- Company operates in OTC Markets, indicating lower trading volume/liquidity
Study Highlights Critical Influence of AI-Driven Reputation on Pharma Market Leaders and New Entrants
CAMPBELL, Calif. and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today released its inaugural AI Brand Reputation Index, providing unprecedented insight into how artificial intelligence shapes the perceptions of 50 leading pharmaceutical brands. The comprehensive study identifies key reputation drivers, revealing crucial implications for market leaders and emerging therapies alike.
"As healthcare professionals, patients, and caregivers increasingly rely on AI-driven platforms for information, pharmaceutical brands must understand and actively manage their AI-driven reputations," said Peter Friedman, LiveWorld Chairman and CEO. "This index gives companies actionable insights to strategically enhance their brand positioning and ensure long-term success."
Key Findings from the Report Include:
- Market Leaders Confirmed: Brands with high consumer familiarity and proven efficacy, such as Dupixent, and Keytruda, demonstrated robust AI reputations, driven by clinical effectiveness and healthcare professional trust.
- Advertising Not the Only Driver: Vertex Pharmaceuticals' Trikafta topped the rankings despite limited advertising, showcasing the power of clinical efficacy, healthcare provider endorsement, and authentic patient advocacy in building AI-driven brand perception.
- Challenges for New Therapies: Emerging drugs like Leqvio and Rybrevant struggle with AI visibility, highlighting immediate opportunities for strategic content marketing.
- Safety Perceptions Persist: Products with perceived safety concerns, such as Remicade and Xeljanz, face significant hurdles in AI-driven reputation, underscoring the lasting impact of safety profiles.
- Accessibility Matters: Brands recognized for affordability and patient-friendly access, including Farxiga and Jardiance, enjoyed enhanced AI-driven sentiment.
The study utilizes LiveWorld’s proprietary AI framework assessing seven weighted reputation factors across prominent large language models (LLMs) including ChatGPT (GPT-4), Perplexity, and Grok. These factors encompassed efficacy, safety, healthcare professional trust, consumer sentiment, digital visibility, affordability, and patient loyalty.
Based on the rankings, the study recommends strategic approaches for pharma companies to build up their brand reputation starting with investing in AI-powered brand monitoring and continuous reputation management.
"AI-driven reputation management is no longer optional—it is a strategic imperative," added Friedman. "Brands that proactively engage with their AI presence will significantly outperform their competition."
Helpful Links:
- LiveWorld AI Brand Reputation Index for Pharma Top 50 Brands
- Brands interested in requesting a customized AI brand reputation report for their brand with competitive comparisons may contact us here.
About LiveWorld
LiveWorld is a social-first digital agency and software company that unlocks the full potential of social media to transform customer relationships through integrated compliance, engagement, and insight solutions. We provide brand marketers bold creative rooted in strategy that captivates and resonates, social moderation and engagement that activates interactions, software that enriches customer experiences, and compliance that enables and accelerates digital programs.
With over 28 years of making connections, we leverage our social media DNA to deliver emotion-driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld.
LiveWorld Contact
PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739
FAQ
What are the key findings of LiveWorld's (LVWD) AI Brand Reputation Index for pharmaceutical brands?
How does LiveWorld (LVWD) measure AI-driven pharmaceutical brand reputation?
Which pharmaceutical brands performed best in LiveWorld's (LVWD) AI reputation study?
What challenges did LiveWorld's (LVWD) study identify for new pharmaceutical therapies?
How do safety concerns affect pharmaceutical brands' AI reputation according to LiveWorld (LVWD)?
